CytRx Gets FDA Go-Ahead To Study Stalled ALS Drug Under Revised Protocol
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
CytRx's potentially disease-altering approach for neurological disorders got a new lease on life after FDA accepted a revised trial protocol and said the company could continue its Phase IIb trial in amyotrophic lateral sclerosis (Lou Gehrig's disease) patients, the firm announced Dec. 2
You may also be interested in...
"Groupthink" Leads Big Pharma To Downplay Neurosciences At Industry's Peril
A generation of potentially useful drugs for neurologic disorders may be lost if something isn't done to shore up early stage companies being "strangled fiscally" by the shift in partnering and financing toward later-stage projects, says Harry Tracy, president of NI Research
Cephalon Reinvention Puts Biologics Front And Center
Through several acquisitions and alliances completed over the last year, Cephalon has patched together a substantial pipeline of biologic drugs, an area of business the specialty pharma is ramping up as it looks to diversify its portfolio beyond wakefulness and pain
CytRx Picks Up Four Clinical-Stage Oncology Candidates With Innovive Acquisition
Biopharma separately plans additional toxicology tests for ALS candidate arimoclomal to address clinical hold imposed by FDA.